BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 17678886)

  • 1. Influence of 17q gain and promoter polymorphisms on mRNA expression of somatostatin receptor type 2 in neuroblastoma.
    Simi L; Pinzani P; Raggi CC; Pazzagli M; Orlando C
    Clin Chim Acta; 2007 Sep; 384(1-2):149-54. PubMed ID: 17678886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin receptor type 2 gene expression in neuroblastoma, measured by competitive RT-PCR, is related to patient survival and to somatostatin receptor imaging by indium -111-pentetreotide.
    Orlando C; Raggi CC; Bagnoni L; Sestini R; Briganti V; La Cava G; Bernini G; Tonini GP; Pazzagli M; Serio M; Maggi M
    Med Pediatr Oncol; 2001 Jan; 36(1):224-6. PubMed ID: 11464890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction.
    Sestini R; Orlando C; Peri A; Tricarico C; Pazzagli M; Serio M; Pagani A; Bussolati G; Granchi S; Maggi M
    Clin Cancer Res; 1996 Oct; 2(10):1757-65. PubMed ID: 9816127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24.
    Abel F; Ejeskär K; Kogner P; Martinsson T
    Br J Cancer; 1999 Dec; 81(8):1402-9. PubMed ID: 10604740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors.
    Briganti V; Sestini R; Orlando C; Bernini G; La Cava G; Tamburini A; Raggi CC; Serio M; Maggi M
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2385-91. PubMed ID: 9815638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type-2 somatostatin receptor mRNA levels in breast and colon cancer determined by a quantitative RT-PCR assay based on dual label fluorogenic probe and the TaqMan technology.
    Pinzani P; Orlando C; Raggi CC; Distante V; Valanzano R; Tricarico C; Maggi M; Serio M; Pazzagli M
    Regul Pept; 2001 Jun; 99(2-3):79-86. PubMed ID: 11384768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome.
    Raggi CC; Maggi M; Renzi D; Calabrò A; Bagnoni ML; Scaruffi P; Tonini GP; Pazzagli M; De Bernardi B; Bernini G; Serio M; Orlando C
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3866-73. PubMed ID: 11061551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYCN overexpression is associated with unbalanced copy number gain, altered nuclear location, and overexpression of chromosome arm 17q genes in neuroblastoma tumors and cell lines.
    Kuzyk A; Booth S; Righolt C; Mathur S; Gartner J; Mai S
    Genes Chromosomes Cancer; 2015 Oct; 54(10):616-28. PubMed ID: 26171843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of single-copy chromosome 17q gain in human neuroblastomas using real-time quantitative polymerase chain reaction.
    Morowitz M; Shusterman S; Mosse Y; Hii G; Winter CL; Khazi D; Wang Q; King R; Maris JM
    Mod Pathol; 2003 Dec; 16(12):1248-56. PubMed ID: 14681326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2.
    Godfried MB; Veenstra M; v Sluis P; Boon K; v Asperen R; Hermus MC; v Schaik BD; Voûte TP; Schwab M; Versteeg R; Caron HN
    Oncogene; 2002 Mar; 21(13):2097-101. PubMed ID: 11960382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular analysis of chromosome arm 17q gain in neuroblastoma.
    Janoueix-Lerosey I; Penther D; Thioux M; de Crémoux P; Derré J; Ambros P; Vielh P; Bénard J; Aurias A; Delattre O
    Genes Chromosomes Cancer; 2000 Jul; 28(3):276-84. PubMed ID: 10862033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.
    Bown N; Cotterill S; Lastowska M; O'Neill S; Pearson AD; Plantaz D; Meddeb M; Danglot G; Brinkschmidt C; Christiansen H; Laureys G; Speleman F; Nicholson J; Bernheim A; Betts DR; Vandesompele J; Van Roy N
    N Engl J Med; 1999 Jun; 340(25):1954-61. PubMed ID: 10379019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcription of SST2 somatostatin receptor gene in human pancreatic cancer cells is altered by single nucleotide promoter polymorphism.
    Torrisani J; Bouisson M; Puente E; Capellà G; Laurent-Puig P; Berger A; Vaysse N; Susini C; Buscail L
    Gastroenterology; 2001 Jan; 120(1):200-9. PubMed ID: 11208729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.
    Bown N; Lastowska M; Cotterill S; O'Neill S; Ellershaw C; Roberts P; Lewis I; Pearson AD;
    Med Pediatr Oncol; 2001 Jan; 36(1):14-9. PubMed ID: 11464868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promiscuous translocations of chromosome arm 17q in human neuroblastomas.
    Lastowska M; Roberts P; Pearson AD; Lewis I; Wolstenholme J; Bown N
    Genes Chromosomes Cancer; 1997 Jul; 19(3):143-9. PubMed ID: 9218994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing histopathological classification with MYCN, 1p36 and 17q status detected by fluorescence in situ hybridisation from 14 untreated primary neuroblastomas in Singapore.
    Yong MH; Hwang WS; Knight LA; Fung W; Chan MY; Seow WT; Chui CH
    Singapore Med J; 2009 Nov; 50(11):1090-4. PubMed ID: 19960166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The studies on the correlation for gene expression of tyrosine-kinase receptors and vascular endothelial growth factor in human neuroblastomas.
    Zhang J; Zheng Y; Wang Y; Tong H
    J Pediatr Hematol Oncol; 2010 Apr; 32(3):180-4. PubMed ID: 20186105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis.
    Casalà C; Gil-Guiñón E; Ordóñez JL; Miguel-Queralt S; Rodríguez E; Galván P; Lavarino C; Munell F; de Alava E; Mora J; de Torres C
    Carcinogenesis; 2013 Feb; 34(2):268-76. PubMed ID: 23108190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin receptor gene expression in neuroblastoma.
    Albers AR; O'Dorisio MS; Balster DA; Caprara M; Gosh P; Chen F; Hoeger C; Rivier J; Wenger GD; O'Dorisio TM; Qualman SJ
    Regul Pept; 2000 Mar; 88(1-3):61-73. PubMed ID: 10706954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYCN amplification and 17q in neuroblastoma: evidence for structural association.
    O'Neill S; Ekstrom L; Lastowska M; Roberts P; Brodeur GM; Kees UR; Schwab M; Bown N
    Genes Chromosomes Cancer; 2001 Jan; 30(1):87-90. PubMed ID: 11107180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.